Status: Recruiting

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (HER2)-negative, programmed death-ligand 1(PD-L1)-positive, unresectable or metastatic gastric or gastroesophageal cancer (GAC/GEA) or esophageal squamous cell carcinoma (ESCC). The study duration will be up to approximately 6 years.

Participants needed: 30

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeOne MedicinesUpdated: Jun 22, 2026Locations: 2

Eligibility criteria

Self-identifies as a member of racial and/or ethnic minority populations as defi... [+8]

Patient has squamous cell or undifferentiated or other histological type gastric... [+14]

Status: Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

This study was a single-arm, open, multi-center Phase Ib/II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC plus S-1 in first-line treatment of advanced gastroesophageal adenocarcinoma with moderate expression of HER2.

Participants needed: 42

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Chinese PLA General HospitalUpdated: Jan 8, 2024Locations: 3

Eligibility criteria

At the same time, patients voluntarily participated in the study and signed info... [+8]

Five years before first use of the study drug has been diagnosed as other malign... [+5]